SenesTech Inc (NASDAQ:SNES) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $0.61 and last traded at $0.66, with a volume of 328800 shares. The stock had previously closed at $0.68.
Several research firms have issued reports on SNES. Zacks Investment Research downgraded SenesTech from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Craig Hallum set a $3.00 price objective on SenesTech and gave the stock a “buy” rating in a report on Wednesday, November 22nd.
The company has a debt-to-equity ratio of 0.17, a current ratio of 2.94 and a quick ratio of 2.67.
Institutional investors and hedge funds have recently modified their holdings of the company. White Pine Capital LLC acquired a new position in shares of SenesTech in the 2nd quarter worth approximately $110,000. Skylands Capital LLC grew its position in shares of SenesTech by 139.8% in the 3rd quarter. Skylands Capital LLC now owns 87,483 shares of the company’s stock worth $162,000 after acquiring an additional 51,000 shares in the last quarter. TCI Wealth Advisors Inc. acquired a new position in shares of SenesTech in the 3rd quarter worth approximately $748,000. Prudential PLC grew its position in shares of SenesTech by 49.3% in the 2nd quarter. Prudential PLC now owns 447,971 shares of the company’s stock worth $2,661,000 after acquiring an additional 147,971 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC grew its position in shares of SenesTech by 3.0% in the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,078,499 shares of the company’s stock worth $1,995,000 after acquiring an additional 31,330 shares in the last quarter. Institutional investors own 14.44% of the company’s stock.
SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.